Stay updated with breaking news from Nasdaq mrns. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Equities analysts expect Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS – Get Rating) to post earnings of ($0.53) per share for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Marinus Pharmaceuticals’ earnings, with estimates ranging from ($1.03) to $1.47. Marinus Pharmaceuticals posted earnings of ($0.65) per share in the same quarter last year, […] ....
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS – Get Rating) – Stock analysts at SVB Leerink issued their FY2026 earnings per share estimates for shares of Marinus Pharmaceuticals in a research note issued on Thursday, May 12th. SVB Leerink analyst M. Goodman forecasts that the biopharmaceutical company will post earnings of $4.85 per share for the year. SVB […] ....
HC Wainwright reissued their buy rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Get Rating) in a report issued on Tuesday, MarketBeat reports. The firm currently has a $38.00 price target on the biopharmaceutical company’s stock. MRNS has been the subject of several other reports. Truist Financial boosted their price objective on shares of Marinus […] ....
Marinus Pharmaceuticals (NASDAQ:MRNS – Get Rating) had its target price trimmed by SVB Leerink from $30.00 to $27.00 in a report published on Tuesday, Marketbeat Ratings reports. They currently have an outperform rating on the biopharmaceutical company’s stock. A number of other research analysts also recently commented on the company. JMP Securities boosted their target […] ....
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS – Get Rating) has been given a consensus recommendation of “Buy” by the eight research firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have assigned a buy recommendation to the […] ....